CN108404019A - Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance - Google Patents
Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance Download PDFInfo
- Publication number
- CN108404019A CN108404019A CN201810392491.7A CN201810392491A CN108404019A CN 108404019 A CN108404019 A CN 108404019A CN 201810392491 A CN201810392491 A CN 201810392491A CN 108404019 A CN108404019 A CN 108404019A
- Authority
- CN
- China
- Prior art keywords
- parts
- galangal
- hyperuricemia
- cape jasmine
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 235000007542 Cichorium intybus Nutrition 0.000 title claims abstract description 22
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 22
- 239000007787 solid Substances 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000723343 Cichorium Species 0.000 title claims description 15
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 42
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 41
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 40
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 39
- 239000001509 sodium citrate Substances 0.000 claims abstract description 26
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000284 extract Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 238000003795 desorption Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 48
- 239000003814 drug Substances 0.000 abstract description 33
- 229940079593 drug Drugs 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 15
- 208000002193 Pain Diseases 0.000 abstract description 11
- 230000036407 pain Effects 0.000 abstract description 11
- 244000298479 Cichorium intybus Species 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 230000002124 endocrine Effects 0.000 abstract description 6
- 230000001976 improved effect Effects 0.000 abstract description 6
- 230000004144 purine metabolism Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000009977 dual effect Effects 0.000 abstract description 4
- 230000001771 impaired effect Effects 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 3
- 210000001835 viscera Anatomy 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 48
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 48
- 229940116269 uric acid Drugs 0.000 description 48
- 230000000694 effects Effects 0.000 description 43
- 235000011083 sodium citrates Nutrition 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 235000016709 nutrition Nutrition 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 230000029142 excretion Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 102100033220 Xanthine oxidase Human genes 0.000 description 9
- 108010093894 Xanthine oxidase Proteins 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000012259 ether extract Substances 0.000 description 6
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000030159 metabolic disease Diseases 0.000 description 5
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 4
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 201000005569 Gout Diseases 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000002279 cholagogic effect Effects 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- -1 crocins compound Chemical class 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001466 anti-adreneric effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 150000000193 1,8-cineol derivatives Chemical class 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000106835 Bindesalat Species 0.000 description 1
- 235000000318 Bindesalat Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- WNBCMONIPIJTSB-TVKJYDDYSA-N Cichoriin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1C=CC(=O)O2 WNBCMONIPIJTSB-TVKJYDDYSA-N 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 241000374160 Cichorium glandulosum Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical class C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000133134 Saussurea Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010064926 acyl-CoA carboxylase Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960005143 amobarbital sodium Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000006193 cichoric acid Nutrition 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 239000001905 cichorium intybus l. root extract Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- XOXYHGOIRWABTC-UHFFFAOYSA-N gentisin Chemical compound C1=C(O)C=C2C(=O)C3=C(O)C=C(OC)C=C3OC2=C1 XOXYHGOIRWABTC-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229950002932 hexamethonium Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- VJQAFLAZRVKAKM-QQUHWDOBSA-N lactucin Chemical compound O[C@@H]1CC(C)=C2C(=O)C=C(CO)[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 VJQAFLAZRVKAKM-QQUHWDOBSA-N 0.000 description 1
- VJQAFLAZRVKAKM-UHFFFAOYSA-N lactucine Natural products OC1CC(C)=C2C(=O)C=C(CO)C2C2OC(=O)C(=C)C21 VJQAFLAZRVKAKM-UHFFFAOYSA-N 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- RSMUVYRMZCOLBH-UHFFFAOYSA-N metsulfuron methyl Chemical compound COC(=O)C1=CC=CC=C1S(=O)(=O)NC(=O)NC1=NC(C)=NC(OC)=N1 RSMUVYRMZCOLBH-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 208000002089 myocardial stunning Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000019617 piquancy Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- BNHGKKNINBGEQL-UHFFFAOYSA-M sodium;5-ethyl-5-(3-methylbutyl)pyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CC(C)CCC1(CC)C(=O)NC(=O)[N-]C1=O BNHGKKNINBGEQL-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides the solid articles and preparation method thereof that a kind of compound chicory root adjusts purine metabolic disturbance.It provides a kind of purine metabolic disturbance applied to hyperuricemia crowd and prevents the product of hyperuricemia complication.The present invention puies forward its host agent using natural medicine-food dual purpose plant cichory root, cape jasmine, galangal, essence, is made with sodium citrate scientific matching, is free of any artificial synthetic, is all natural type.Human body purine metabolism can be enhanced after taking, body internal organs adjusting is carried out, be conducive to that the pain of patient, red heat symptom etc. is made to be improved, the function situation between each organ of body is gradually adjusted, adjust impaired organism endocrine.Present invention process is simple, at low cost, is easily obtained active component, is suitable for industrialized production, can be used for being prepared into the purine metabolic disturbance for improving hyperuricemia crowd and prevents food, drug or the health products of hyperuricemia complication.
Description
Technical field
The present invention relates to technical field of food healthcare, specifically a kind of compound chicory root adjusts the solid of purine metabolic disturbance
Product and preparation method thereof.
Background technology
In recent years, with the promotion of social standard of living, also huge variation is occurring for the dietary structure of people.People
It is growing day by day to high sugar, high protein, the intake of high purine group food, cause body also keeping body dirty while absorbing nutrition
Device carries out the operating of high load capacity.Therefore, the incidence of all kinds of metabolic diseases shows the trend risen year by year.
Hyperuricemia (Hyperuricemia, HUA) is one group with heredity and (or) acquired uric acid excretion is caused to subtract
Less and (or) internal disorders of purine metabolism, cause a kind of disease that blood uric acid increases [C.Remedios, M.Shah,
A.G.Bhasker, et al.Hyperuricemia:A Reality in the Indian Obese [J] .OBES SURG,
2012,22:945-948.].As people's living standard improves and lifestyle change, the incidence of hyperuricemia by
Year increases (10% or more), but the early stage of hyperuricemia is asymptomatic, and only blood uric acid duration or fluctuation increase, from blood
Uric acid be increased to symptom appearance time be the several years to many decades [in of heap of stone from blood it is turbid opinion control primary asymptomatic height urinate
The Jinan clinical research [D] of acidaemia:Shandong Traditional Chinese Medicine University, 2009.];And most people is to the cognition degree of hyperuricemia
Relatively low, lower to diet Rural Residents ' Knowledge about Hypertension [Chen Zhiming, He Xiaoqin health educations are to Patients with Hyperuricemia intervention effect
Evaluate the Zhejiang [J] preventive medicine, 2010,22 (10):82-83.], so often getting the brush-off.
Now with living-pattern preservation, the uric acid that body generates increases, in the human body of normal renal function, may pass through
The excretion for increasing urine uric acid and the capacity (tissue deposition) for increasing uric acid pond come compensatory.It is compensatory for a long time to lead to renal impairment,
Compensatory capacity declines, and the excretion of uric acid is reduced, and the deposition of tissue increases.At this time, it may be necessary to inhibit by the treatment of drug
The generation of uric acid or the excretion for promoting uric acid.
Domestic and international massive epidemiology and clinical studies show, hyperuricemia are not only single common metabolic disease
Disease, it is close with numerous cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, artery sclerosis, heart failure, myocardial infarction and cerebral apoplexy
Cut phase is closed, and the human bodies organ-tissue such as kidney, liver, joint can be also involved, even its independent risk factor [the new of Guo Li without
Symptom hyperuricemia merges Prespect of Diagnosis of Cardiovascular Diseases and suggests that Chinese Consensus of experts understands the practical internal medicine journal of [J] China,
2011,31 (4):271-273.].Therefore, by the analysis to hyperuricemia harmfulness, general public and medical care are reminded
Personnel, it is understood that the necessity of hyperuricemia drug therapy is the task of top priority.
Since limit purine diet can only slightly reduce UA, to the Patients with Hyperuricemia of blood UA high, individually selection limit is fast
Purine diet, effect is limited.Therefore, drug [Liu Pingli, Zhang Chengli the asymptomatic hyperuricemias of anti-trioxypurine need to be applied
Disease diagnoses and treats in [J]
State's Excerpta Medica clinical practice, 2002,4:27.]:
1. reduce uric acid maintains uric acid crystal saturation point or less (6mg/dL or 360 μm of ol/L), other purine by blood UA levels
Alcohol is effective drug for inhibiting uric acid to generate, should be since low dose (100mg/d);But there is allergic dermatitis, hepatic disorder,
Acute hepatocellular necrosis, upper gastrointestinal bleeding, the adverse reactions such as bone marrow suppression are treated asymptomatic hyperuricemia and are not recommended.
2. promoting the available sulfinpyrazone (narcaricin) of uric acid excretion, but renal hypofunction person disables.
3. having tophaceous deposition, and renal hypofunction does not show author, can merge using the above two classes drug, or with " leading to
Beneficial wind is peaceful " piece (containing allopurinol and narcaricin).
4. Febuxostat (Feluxostat) [Becker MA, Schumacher HR, Wortmann RL, et
al.Febuxostat compared with allopurinol in patients with hyperuricemia and
Gout [J] .N Engl J Med, 2005,353 (23):2450-2461.] it is a kind of new xanthine oxidase inhibitor,
In European and American countries application, but its company claims that the medicine is not recommended to be used for asymptomatic hyperuricemia.
5. hyperuricemia is associated with hypertension, coronary heart disease, diabetes, urinary tract infections, renal failure etc., except according to etiological treatment
Outside, to consider plus use the drug of drop UA;Melbine, Atorvastatin, fenofibrate, Losartan, Amlodipine are in hypoglycemic, tune
While fat, decompression, there is different degrees of anti-trioxypurine effect, application may be selected, but should not use long.Therefore, 2 types sugar is being treated
On complex disease as urine disease, compared with chemicals, Chinese medicine has unrivaled advantage.
Currently, the asymptomatic hyperuricemia of clinical treatment still lacks safe and effective ideal medicament.
Hyperuricemia finds for biochemical analysis, though it is somebody's turn to do without the record specifically for " hyperuricemia " in traditional Chinese medicine
Disease be developed to middle and later periods initiation " gout " belong to the sick scope such as Chinese medical ' arthralgia syndrome ', " joint-running ", " athlete's foot " [Chen LY,
Zhu WH, Chen ZW, et al.Relationship between hyperuricemia and metabolic
Syndrome [J] .JZUS-B, 2007,8:593-598.- Guo Jing, king lack the dietetic regulation of the asymptomatic hyperuricemias of outstanding person
It is debated with Chinese medicine and controls thinking [J] Beijing University of Chinese Medicine journal, 2010,33 (11):786-788.].Chinese medicine always payes attention to disease
Prevention, it is proposed that the thought of " sage's preventing diseases instead for the treatment of diseases ".Traditional Chinese medicine has been pushed to new forward position by the transition in epoch, with
The change of human habitat, environmental pollution, bad life style and feelings will internal injury have become new pathogenic factor, spectrum of disease
Change, a large amount of appearance of silent disese, Chinese medicine by hoping, hear, asking, cutting the needs that the four methods of diagnosis cannot be satisfied clinical diagnosis,
The result that doctor trained in Western medicine clinical examination should be intimately associated is diagnosed, and the Chinese traditional treatment to hyperuricemia is actively developed, and plays Chinese medicine
Medicine advantage.
Therefore, with the idea of " people is organic whole ", from traditional Chinese and western medicine clinical practice, in conjunction with Developments, fortune
With natural medicine-food dual purpose plant, the new approaches of hyperuricemia are prevented from adjusting endocrinal environment angle.According to patient clinical disease
Existing difference between shape and constitution is specific to choose the natural medicine-food dual purpose plant progress body internal organs tune for adjusting purine metabolic disturbance
Section, is conducive to that the pain of patient, red heat symptom etc. is made to be improved, and gradually adjusts the function situation between each organ of body, moreover it is possible to
It is enough obviously to reach the curative effects such as Wen Yang, dredging collateral, help to promote control effect.
Compound chicory root adjusts purine metabolic disturbance solid product:Its using natural medicine-food dual purpose plant cichory root,
Cape jasmine, galangal, essence put forward its host agent, are made with sodium citrate scientific matching, are free of any artificial synthetic, are all natural
Type.Therefore, the product for studying purine metabolic disturbance is the emphasis that today's society is paid close attention to jointly.In conclusion exploitation integration of drinking and medicinal herbs
Natural improvement purine metabolic disturbance product will have extremely wide foreground.
Invention content
The purpose of the present invention is to solve the above-mentioned problems of the prior art, and then provide a kind of compound chicory root tune
Save purine metabolic disturbance solid articles and preparation method thereof, act on prevention hyperuricemia crowd purine metabolic disturbance and
Prevent hyperuricemia complication.
The purpose of the present invention is what is be achieved through the following technical solutions:
A kind of compound chicory root adjusts the solid articles of purine metabolic disturbance, based on cichory root, cape jasmine, galangal, extract
Raw material is wanted, sodium citrate is equipped with and is mixed, wherein the weight proportion of various raw materials is:9-30 parts of cape jasmine of 9-30 portions of cichory root is high
0.5-3 parts of sodium citrate of 9-30 parts of galingal.
Further, the weight proportion of various raw materials is:9-15 portions of cichory root 9-15 portions of cape jasmine 9-15 portions of lemons of galangal
Sour sodium 1-2 parts.
Further, the weight proportion of various raw materials is:15 parts of cichory root, 15 parts of cape jasmine, 15 parts of sodium citrates 2 of galangal
Part.
A kind of preparation method of the solid articles of compound chicory root adjusting purine metabolic disturbance,
A, it takes cichory root, cape jasmine, galangal to be pulverized and mixed, is put into water extractor, solution is moisturized within 12 hours with 65 degree of soaking in Chinese liquor
It inhales, solid-liquid ratio 1:1.5~2.0 times.
B, distilled water is heated to 100 DEG C, be added in the extractor for being placed with cichory root, cape jasmine, galangal desorption powder, filter carries
Secondary, each 5min merges extracting solution, is concentrated into medicinal extract, is dried under reduced pressure, to be ground into 80 mesh powder spare.
C, spare powder is taken, gradient mixing is carried out in right amount with sodium citrate, dextrin, is pelletized, packing obtains solid articles.
The beneficial effects of the invention are as follows:By using technical scheme of the present invention, the natural edible of integration of drinking and medicinal herbs is selected to plant
Object is raw material, and each component meets food pharmaceutical control and administration law regulation, and adjusting human body purine metabolism using the comprehensive function of each taste balances, improve by
The organism endocrine metabolic disorder of damage.It is non-toxic to humans without chemical addition agent.
Present invention process is simple, at low cost, is easily obtained nutritional ingredient position, is suitable for industrialized production, can be used for making
It is standby at human body purine metabolism balance is adjusted, improve answering for the drug of impaired organism endocrine metabolic disorder, food or health products
With.
Specific implementation mode
The present invention is described in further detail below:The present embodiment under based on the technical solution of the present invention into
Row is implemented, and gives detailed embodiment, but protection scope of the present invention is not limited to following embodiments.
A kind of compound chicory root involved by the present embodiment adjusts the solid articles of purine metabolic disturbance, with cichory root, Cape jasmine
Son, galangal, extract are primary raw material, are equipped with sodium citrate and are mixed, wherein the weight proportion of various raw materials is:Witloof
9-30 parts of root 9-30 parts of cape jasmine 0.5-3 parts of sodium citrate of 9-30 parts of galangal.
Preferably, the weight proportion of various raw materials is:9-15 parts of cichory root 9-15 parts of cape jasmine 9-15 parts of citric acids of galangal
1-2 parts of sodium.
Preferably, the weight proportion of various raw materials is:15 parts of cichory root, 15 parts of cape jasmine, 15 parts of galangal, 2 parts of sodium citrate.
A kind of preparation method of the solid articles of compound chicory root adjusting purine metabolic disturbance,
A, it takes cichory root, cape jasmine, galangal to be pulverized and mixed, is put into water extractor, solution is moisturized within 12 hours with 65 degree of soaking in Chinese liquor
It inhales, solid-liquid ratio 1:1.5~2.0 times.
B, distilled water is heated to 100 DEG C, be added in the extractor for being placed with cichory root, cape jasmine, galangal desorption powder, filter carries
Secondary, each 5min merges extracting solution, is concentrated into medicinal extract, is dried under reduced pressure, to be ground into 80 mesh powder spare.
C, spare powder is taken, gradient mixing is carried out in right amount with sodium citrate, dextrin or soluble starch, is pelletized, packing obtains
To solid articles.
One important feature of complex solid product of the present invention is to contain abundant nutritional ingredient position, wherein chrysanthemum in product
Chlorogenic acid, aesculin, Cichoric acid contained in lettuce root are good anti-trioxypurine active constituents, and safety is preferable, play medicine
The mechanism of effect may be related with XOD, ADA activity is inhibited;Contain Gardenoside and crocins compound in cape jasmine, there is part
By inhibiting the activity of xanthine oxidase to reduce serum uric acid level, and there may be other anti-trioxypurine approach;Gao Liang
Flavonoids, volatile oil and diaryl heptane substance for containing in ginger etc. have significant xanthine oxidase (XOD) inhibitor
Effect.Also there is antiulcer, anti diar rhea, adjust bowel movement, cholagogic, anti-pain, anti-inflammatory, anti anoxia, anti-freezing, antithrombus formation etc.
Effect.
Complex solid product nutritional ingredient position of the present invention is through preliminary edible identification:Human body purine metabolism can be enhanced, carried out
Body internal organs are adjusted, and are conducive to that the pain of patient, red heat symptom etc. is made to be improved, and gradually adjust the running between each organ of body
Situation adjusts impaired organism endocrine, therefore, can be developed into answering for the drug for preventing hyperuricemia, food or health products
With.
Hyperuricemia (HUA) refers to the non-empty stomach serum uric acid level male twice on the same day under normal purine diet state
Higher than 420 μm ol/L, women are higher than 360 μm of ol/L, i.e. referred to as hyperuricemia.
1. the standard of hyperuricemia
Under normal purine diet state, non-empty stomach serum uric acid level is male twice on the same day>416.5 μm of ol/L or female>357μmol/L.
2. the classification diagnosis of hyperuricemia
Classification diagnosis helps to find the cause of disease of hyperuricemia, gives immunotherapy targeted autoantibody.The low purine drink of Patients with Hyperuricemia
Food leaves and takes twenty-four-hour urine detection urine uric acid level after 5 days.
(1) good figure uric acid excretion is not less than 2.86 μm of ol/ (kgh) to uric acid excretion, and uric acid clearance is less than 6.2ml/
min。
(2) uric acid generated many types of uric acid excretion more than 3 μm of ol/ (kgh), and uric acid clearance is greater than or equal to 6.2ml/
min。
(3) mixed type uric acid excretion is more than 3 μm of ol/ (kgkh), and uric acid clearance is less than 6.2ml/min.
Influence in view of renal function to uric acid excretion, is corrected with creatinine clearance rate, is removed according to uric acid clearance/creatinine
Rate ratio is as follows to hyperuricemia parting:>10% for uric acid generated it is many types of;<5% is uric acid excretion not good figure;5%~
10% is mixed type.
Random blood uric acid blood uric acid instrument
Uric acid instrument on the market and blood glucose meter belong to capillary detection.Whether it oneself surveys or arrives hospital, only with capillary
Blood vessel detection all cannot be used for diagnosing, and its precision and hospital's venous blood detection also have certain deviation.
When patient's serum uric acid level is higher, the probability that error occurs in the test of uric acid instrument also can accordingly increase, and range up to 200
Left and right, but actually this problem have no effect on uric acid instrument be truly present value --- observation of curative effect and medication monitoring.
Patients with Hyperuricemia takes the variation of uric acid level (umol/l) (after 7 days) before and after product
Before A takes | After B takes | |
780 | 520 | |
630 | 530 | |
850 | 560 | |
650 | 480 | |
770 | 392 | |
700 | 480 | |
630 | 480 | |
790 | 390 | |
860 | 570 | |
740 | 520 | |
710 | 495 | |
560 | 465 | |
540 | 360 | |
680 | 605 | |
610 | 460 | 1.80229E-07 |
Result of study illustrates that compound chicory root adjusts purine metabolic disturbance solid articles and can effectively improve human body purine metabolism
Adjust disorderly reduction serum uric acid level (P<0.01);
Compound chicory root adjusts the natural adjusting human body purine metabolism balance that purine metabolic disturbance solid articles are integration of drinking and medicinal herbs, changes
It is apt to impaired organism endocrine metabolic disorder, there will be extremely wide foreground.
Cichory root in this product, cape jasmine, the nutritional ingredient of galangal and sodium citrate physiological function:
1. being feverfew saussurea intybus Cichorium glandulosum Boiss.et Hout and witloof Cichorium
The root of intybus L. dryings.Autumn excavates, and removes impurity, dries.
Witloof contains moisture (94.18%), soluble solid (4.43%), vitamin C (22.8mg/100g), thick egg
(2.02%), 17 kinds of amino acid (1.34g/100g) in vain, zinc (0.310mg/kg), calcium (73.8mg/100g), Organic Selenium
Containing fructose (5.247mg), glucose (2.181mg), sucrose in (0.0026mg/100g), every 100 grams of witloof dry matters
(0.651mg) and gentianic acid (33.522mg), chlorogenic acid (25.331mg), rutin (17.431mg), caffeic acid
(14.700mg), catechin (6.904mg), salicylic acid (6.852mg), epicatechin (6.011mg), vanillic acid (4.396mg),
Quercetin (4.345mg), syringic acid (2.267mg) etc..Heat has 71.2 kilojoules.Data show that witloof " long romaine lettuce " is a kind of
The very high vegetables of edible value.
Contain aesculetin, aesculin, cichoriin, lactucin, lactucopicin, α-mountain lettuce in witloof
Various trace elements such as alcohol, 17 kinds of amino acid, beta carotene, vitamin A, vitamin C and calcium, potassium, sodium, selenium, zinc and prebiotic
(prebiotics (Prebiotics) refer to the food composition for being not easy to be digested to member, pass through the stimulation one or more bacterium of selectivity
Growth with activity and to host generate wholesome effect, so as to improve the substance of host health.Prebiotics include mainly various
Oligosaccharides substance (Oligosaccharides) or oligosaccharide (being made of 2~10 molecule monosaccharide).More generally method is
Functional oligose.) etc. ingredient with high nutritive value.So many nutritional ingredient make witloof have be adjusted in synchronism blood fat,
Blood glucose, blood uric acid, that is, improve unique pharmacological activity of human endocrine disorder, while can be effectively improved human flora's distribution, adjusts
Section functions of intestines and stomach, gut purge defaecation, fall fire are moisturized, slim skin care, are enhanced human immunity, not to cerebrovascular sclerosis, nutrition
The diseases such as benign anaemia have certain protective action, and are also the greasy preferred good merchantable brand of meat or fish that relieves the effect of alcohol.
Cichory root contain synanthrin and aromatic substance, promote human digestive organ activity, have clearing heat and detoxicating, inducing diuresis to remove edema, stomach invigorating,
Hypoglycemic, lipid-loweringing, anti-trioxypurine and other effects.Multinomial research experiment shows that cichory root has the function of Adjust-blood lipid and anti-trioxypurine, urinates height
Sour triacylglycerol mass formed by blood stasis has good adjustment effect, and can obviously improve the hyperuricemia caused by high purine diet and
Central obesity.Its mechanism of action may be by reducing liver acyl CoA carboxylase enzyme, fatty acid synthetase and xanthine oxidase
Change enzymatic activity, to play the effect of comprehensive adjustment uric acid and abdominal fat accumulation.It is edible and medicinal that cichory root is that one kind has both
The special plant of two kinds of functions is classified as " integration of drinking and medicinal herbs class " food by the Ministry of Public Health, while being praised by National Nutrient alliance expert
For green " king of health ".There are some researches prove cichory root active principles can significantly reduce uric acid, the blood glucose caused by hyperglycemia
It increases, and the effect that the interaction of comprehensive adjustment fat, sugar, uric acid is disorderly.Chicory root extract can obviously improve to be drawn by high purine diet
The hyperuricemia and Central obesity of hair, to play the effect of comprehensive adjustment uric acid and abdominal fat accumulation.
For convenience of eating, cichory root has been made into entering our life on behalf of the tea.By cichory root dry shred, frying at
Cichory root tea is also blue chrysanthemum root tea, more convenient edible daily, if it is daily maintenence, can 10g is soaked daily drinks, such as
Fruit is auxiliary treatment reducing blood lipid, and anti-trioxypurine ensures 10-20g daily.
2. cape jasmine (Garadenia jasminoides), also known as Yellow Fructus Gardeniae, mountain Cape jasmine, Fructus Gardeniae etc., are rubiaceous one kind
Evergreen shrubs, main product is in Jiangxi, Zhejiang, Hunan and other places.Cape jasmine fruit system traditional Chinese medicine also falls within first medicine of Ministry of Public Health's promulgation
Dual-purpose resource is eaten, has the effects that protect liver, cholagogic, decompression, hemostasis, heat-clearing.Cape jasmine is mainly cape jasmine fruit using part
And gardenia, the complex chemical composition of cape jasmine fruit include mainly crocin class, glucoside and polyatomic phenol, additionally contain fruit
20 various trace elements such as glue, mannitol and Fe, Mn, Zn, Cu;Gardenia essential oil containing cape jasmine is the master for refining gardenia compound
Want raw material.
The fruit of Chinese medicine cape jasmine has edible value, and taste of tasting is equally sweet just as honey.Chinese medicine cape jasmine fruit
There are malic acid and vitamins and other nutritious components in reality, more valuable is also abundant zinc and selenium element.They are high nutritions
Substance gives human body basic nutrition supplement.
The dietary function of cape jasmine
There is liver protection effect, hepatic injury caused by chlorination carbon can be mitigated, mitigates the denaturation and necrosis of liver cell.Choleresis can be increased,
Promote bile excretion;Stomachial secretion is reduced, gastrointestinal peristalsis is promoted;Also calm, analgesia, anti-inflammatory, antibacterial effect;In addition there is drop blood
Pressure reduces myocardial contractive power, makes decreased heart rate, blood vessel dilatation.It is anti-inflammatory.Gardenoside can inhibit inflammation early stage oedema, exudation and inflammation
The hyperblastosis in disease late period and granulation tissue generate, and can especially resist brain inflammation.
Antipyretic-antalgic.Gardenoside can effectively inhibit the writhing pain reaction that acetic acid induces, and show analgesic activity;It is apparent to rise
The threshold of pain that height stimulates hot plate;There is sedation, can also be obviously prolonged influence of the amobarbital sodium to sleeping time.
Hepatic cholagogic.Gardenoside can effective liver protection, increase bile flow, reduce bile inner cholesterol content, prevent courage solid
Alcohol calculus.
Protect nervous system.Gardenoside passes through pro-inflammatory cytokine and blood plasma medium vessels hemogenia after inhibition cerebral ischemia
Factor expression plays the protective effect to secondary brain injury.Capejasmine extract geniposide can extend social interaction time, have
Antianxiety Activity.Geniposide can protect nerve, and have potential anti-Alzheimer disease to act on.
Protect cardiovascular system.Cape jasmine ethanol extract can treat atherosclerosis.Crocetin can reduce in serum
Creatine kinase and lactate dehydrogenase activity, alleviate myocardial stunning, improve myocardial ischemia, prevent myocardial infarction.Cape jasmine Chinese and Western is red
Flower glycosides and its metabolin crocetin can inhibit pancreatic lipase activity, significantly reduce serum triacylglycerol, total cholesterol, low density lipoprotein
Protein cholesterol and C-VLDL reduce blood fat.Geniposide and its metabolite Geniposide can inhibit phosphorus
The activity of resin acid enzyme resists thrombus.
Treatment at present clinically by cape jasmine for gout is also more, and having document report capejasmine extract to have reduces
[Zhu Jixiao, Zeng Jinxiang, Luo Guangming wait cape jasmine anti-trioxypurine active components to grind for the effect of the mouse high lithemia of Oteracil Potassium induction
Study carefully Chinese experimental pharmacology of traditional Chinese medical formulae magazines, 2012,18 (14): 160~161., Zhu Jixiao, Zhu Yuye, Luo Guangming wait cape jasmines to extract
Object reduces chmice acute hyperuricemia serum uric acid level and mechanism study Agriculture of Anhui science, 2011,39 (36): 22317~
22318,22324.].3. galangal
Galangal nutritional ingredient
Heat | 169 kilocalories | Thiamine | 0 milligram | Calcium | 75 milligrams |
Protein | 10.9 grams | Riboflavin | 0.31 milligram | Magnesium | 0 milligram |
Fat | 5.7 gram | Niacin | 0 milligram | Iron | 0.5 milligram |
Carbohydrate | 18.6 grams | Vitamin C | 0 milligram | Manganese | 36 milligrams |
Dietary fiber | 43.3 grams | Vitamin E | 3.65 milligram | Zinc | 4.99 milligram |
Vitamin A | 0 microgram | Cholesterol | 0 milligram | Copper | 0.62 milligram |
Carotene | 8.8 microgram | Potassium | 87 milligrams | Phosphorus | 8 milligrams |
Retinol | 12.7 micrograms | Sodium | 7.5 milligram | Selenium | 12.6 micrograms |
Galangal nutritional ingredient:Here it is the nutrient content in 100 grams of edible portions in galangal.
Food portion:For the edible portion of every 100 grams of food (inedible part includes skin, seed etc.).
Content:For the nutrient content of 100 grams of food portions (it can be served part).
Galangal trophic analysis:Rhizome contains Galangin (Galangin), kaempferia galanga (Kaempferide) Quercetin
(Quercetin) and volatile oil.The main component of oil is 1,8- Cineoles (1,8-Cineole) and cinnamic acid formicester (Methyl
cinnamate).The piquancy component of galangal is galangol (Galangol).There is the work of warm taste, cold-dispelling, promoting qi circulation and relieving pain
With.
Galangal dietary function:The taste is pungent, warm-natured.Returns spleen, stomach.The peppery temperature of virtue dissipates.Warming spleen and stomach for dispelling cold, regulating qi-flowing for relieving pain.It is main
It controls coldness and pain in the epigastrium, vomits hiccup, dysentery, cold hernia, tinea pedis is dysphagic.
Pharmacological action
(1) shows the effect experiment of digestive system:Galangal decoction gives dog gavage, and the total acid output of gastric juice can be made relatively to compare
Group is increased significantly, but is had no significant effect to stomach cardia vigor.To intragastric administration on mice, it can significantly fight atropine and inhibit prepared Chinese ink stomach and intestine
Propulsion rate, and discharge function caused by folium sennae can be fought, but the discharge function of castor oil cannot be fought.Folium sennae is that stimulation is big
Intestines cathartic, and castor oil is stimulation small intestinal cathartic, most drugs for dispelling internal cold are to stimulating big enteral diarrhea to have anti-diarrhea effect.There is report
It points out, galangal water decoction has excitation to the movement of isolated rabbit intestinal tube, and low dose can fight hexamethonium and atropine, larger
Dosage can inhibit antiadrenergic drug and inderal isolated rabbit jejunum activity, cannot then be fought to diphenhydramine.Prompt galangal
Excited intestinal tube activity effect may be unrelated with cholinergic nerve and M- receptors, and may be with it with histamine sample and antiadrenergic drug
Sample effect is related.
(2) in vitro, galangal has inhibiting effect to antibacterial actions to Bacillus tuberculosis.Experiment in vitro proves:Gao Liang
Ginger decocting liquid (100%) is to bacillus anthracis, alpha-Hemolytic streptococcus, beta hemolytic streptococcus, corynebacterium diphtheriae, bacillus pseudodiphthericus, lung
Scorching diplococcus, staphylococcus aureus, Staphylococcus citreus, staphylococcus albus, hay bacillus etc. have different degrees of
Antibacterial action.
(3) other effect galangal water extracts of or volatile oil have anti thrombotic action to rat oral gavage;It can make white pottery
Native partial thromboplastin time is obviously prolonged, but to plasma prothrombin time, prothrombin time elapsed, thrombin time,
V factor, VII factor etc. all have no significant effect, and show that it participates in intrinsic coagulation system, have certain anticoagulation.Water carries
Take object that can obviously inhibit ADP or collagen-induced rabbit platelet aggregation.
Galangal decoction can significantly postpone the mouse pain sensation (hot plate method) reaction time.Before its analgesic activity may inhibit with it
Row parathyrine synthetase series related with phosphate enzyme system
Galangal ether extract and water extract can significantly extend decapitated mice dehisce duration and potassium cyanide poisoning it is small
The time-to-live of mouse;But on the time-to-live of sodium nitrite poisoning mice without influence.Ether extract can extend atmospheric closed anoxic
The time-to-live of mouse and slow down body keto consumpting speed;Water extract makees the time-to-live of atmospheric closed hypoxia mice without extension
With, but the oxygen Utilization ability of mouse under low oxygen conditions can be improved.
(1) warm in pain acts on:
Galangal water extract and ether extract can significantly stress type ulcer and rat hydrochloric acid ulcer to anti-mouse water logging;Water carries
Object has apparent inhibition, two kinds of extracts that can significantly fight diarrhea caused by castor oil, water extract mouse GI tract propulsion
It is also effective to diarrhea caused by folium sennae.Water extract has collaboration transaminase raising effect.Two kinds of extracts have anesthetized rat
Apparent choleretic effect, ether extract effect are stronger.In thermoae method and acetic acid writhing test, two kinds of extracts have apparent analgesia to make
With.
(2) to the influence of microcirculation:Galangal is the warm pain class Chinese medicine of fragrance, has quickly alleviating pain effect to angina pectoris, to slight
Arteriole blood flow caused by adrenaline is set to stop or slow down have retardation function.There is retardation function to caliber contraction time.Right
So that caliber is had restitution (control group continues to shrink) after ten minutes to adrenaline, also arteriole light contraction is acted on.
(3) to the influence of anoxic and the mouse that catches cold:It can extend decapitated mice to intragastric administration on mice galangal ether extract and water extract
It dehisces time-to-live of duration and KCN poisoning mices, but does not influence NaNO2The poisoning mice time-to-live.Ether extract
The time-to-live of atmospheric closed hypoxia mice can also be extended and slow down body keto consumpting speed, water extract does not extend atmospheric closed and lacks
The time-to-live of oxygen mouse, but the oxygen Utilization ability of mouse under low oxygen conditions can be improved.Two kinds of extracts are to the mouse that catches cold
Time-to-live is without influence.
In addition, Galangin, can reduce the serum Uric Acid Concentration of hyperuricemia mouse, mechanism of action may be by pressing down
Xanthine oxidase activity processed reduces uric acid and generates.
Galangal is the dry rhizome of zingiberaceous plant galangal, mainly contains flavonoids, volatile oil and diaryl heptane class
Close object.Have been reported that display, galangal also has the effect of significant xanthine oxidase (XOD) inhibitor, and XOD is catalysis human body
Purine substance is metabolized to the key enzyme of uric acid, inhibits its activity that can reduce internal uric acid concentration, and treatment hyperuricemia [is worn
The screening of xanthine oxidase inhibitor and the Wuhan preparation research [D] in vertical treasure's Chinese herbal medicines:Wuhan Engineering Univ, 2010],
[QuanH, KaQ, FengZ.Hyperuricemia induces endothelial dysfunc~tion via
MitochondrialNa+/Ca2+exchanger-mediated mitochondrial calcium overload [J]
.Cell Calcium, 2012,51 (50):402~410].
4. sodium citrate
Sodium citrate can be used as a kind of food additives, can make foodstuff flavouring, keep food more nice, in good taste, lemon
Sour sodium itself also has certain nutritional ingredient, is added to the nutrition that can increase food in food, and sodium citrate is national permission
The food additives used.
Sodium citrate is a kind of organic compound after all, is a kind of sodium salt, and many people's worries have been eaten can be harmful,
In fact not so, sodium citrate is a kind of substance of alkalinity, and it can be that human body is in a normal ph with balanced human's acid-base value often to eat
It is worth range, also alkalinity is very good to the fatigue after alleviating human motion.Sodium citrate is edible.With following excellent
Benign energy:
(1) safe and non-toxic performance.Due to preparing the raw material basic source of sodium citrate in grain, thus it is reliable to be perfectly safe, right
Human health not will produce harm.The United Nations grain farmer takes the photograph it with the World Health Organization people's amount and is not intended to be limited in any daily, can recognize
Belong to No Poison for the product.
(2) there is biological degradability.Sodium citrate partly becomes citric acid, the two after a large amount of water dilution of nature
It coexists in same system.Citric acid is in water through oxygen, heat, light, bacterium and the effect of microorganism, it is easy to biology drop occur
Solution.It is usually to be changed into carbon dioxide and water through aconitic acid, itaconic acid, Ning Kang Suan Yu that it, which decomposes approach,.
(3) there is complexing of metal ion ability.Sodium citrate has good complexing energy to metal ions such as Ca2+, Mg2+
Power also has good complexing power to other metal ions, such as Fe2+ plasmas.
(4) fabulous solubility property, and dissolubility increases with water temperature and is increased.
(5) there is good pH adjustings and cushion performance.Sodium citrate is a kind of weak acid strong alkali salt, can with compatibility of citric acid
Stronger pH buffer is formed, therefore has its important use in certain occasions for being not suitable for pH wide variations.In addition, citric acid
When sodium is injected as first salt, for correcting blood, body fluid and the acidity of urine, as diuretics, resolving sputum agent etc..
The active component that the preparation method of the present invention is prepared defines, purity is high.Except edible white in entire preparation method
Outside wine, other organic solvents are not used, it is environment friendly and pollution-free.Entire production process is easily achieved the big production of industrialization.
In vitro, internal pharmacodynamics test and preliminary clinical test show by Gao Liang made from preparation method of the present invention
Ginger active component has apparent anti-trioxypurine effect.There is good effect for hyperuricemia or patient with gout.
The foregoing is only a preferred embodiment of the present invention, these specific implementation modes are all based on the present invention
Different realization methods under general idea, and scope of protection of the present invention is not limited thereto, it is any to be familiar with the art
Technical staff in the technical scope disclosed by the present invention, the change or replacement that can be readily occurred in, should all cover the present invention
Within protection domain.Therefore, the scope of protection of the invention shall be subject to the scope of protection specified in the patent claim.
Claims (4)
1. a kind of compound chicory root adjusts the solid articles of purine metabolic disturbance, it is with cichory root, cape jasmine, galangal, extract
Primary raw material is equipped with sodium citrate and is mixed, wherein the weight proportion of various raw materials is:9-30 parts of cape jasmine 9-30 of cichory root
Part 0.5-3 parts of sodium citrate of 9-30 parts of galangal.
2. compound chicory root according to claim 1 adjusts the solid articles of purine metabolic disturbance, the weight of various raw materials
Proportioning is:9-15 parts of cichory root 9-15 parts of cape jasmine 1-2 parts of sodium citrate of 9-15 parts of galangal.
3. compound chicory root according to claim 2 adjusts the solid articles of purine metabolic disturbance, the weight of various raw materials
Proportioning is:15 parts of cichory root, 15 parts of cape jasmine, 15 parts of galangal, 2 parts of sodium citrate.
4. compound chicory root adjusts the preparation method of the solid articles of purine metabolic disturbance,
A, it takes cichory root, cape jasmine, galangal to be pulverized and mixed, is put into water extractor, solution is moisturized within 12 hours with 65 degree of soaking in Chinese liquor
It inhales, solid-liquid ratio 1:1.5~2.0 times;
B, distilled water is heated to 100 DEG C, be added in the extractor for being placed with cichory root, cape jasmine, galangal desorption powder, filter carries two
Secondary, each 5min merges extracting solution, is concentrated into medicinal extract, is dried under reduced pressure, to be ground into 80 mesh powder spare;
C, spare powder is taken, gradient mixing is carried out in right amount with sodium citrate, dextrin, is pelletized, packing obtains solid articles.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810392491.7A CN108404019A (en) | 2018-04-27 | 2018-04-27 | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810392491.7A CN108404019A (en) | 2018-04-27 | 2018-04-27 | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108404019A true CN108404019A (en) | 2018-08-17 |
Family
ID=63137117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810392491.7A Pending CN108404019A (en) | 2018-04-27 | 2018-04-27 | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108404019A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109511984A (en) * | 2019-01-09 | 2019-03-26 | 丁强 | A kind of special dietary seafood with the alleviation gout that celery seed, potassium citrate etc. are primary raw material preparation |
CN110051002A (en) * | 2019-04-28 | 2019-07-26 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine effect |
CN110393249A (en) * | 2019-09-08 | 2019-11-01 | 李丽 | A kind of witloof lily compound solid beverage product and preparation method thereof |
CN110859304A (en) * | 2019-11-26 | 2020-03-06 | 黑龙江惊哲森林食品集团有限公司 | Sunflower disc purine-reducing enzyme and preparation method thereof |
CN113425812A (en) * | 2021-08-06 | 2021-09-24 | 江苏菇神生物科技有限公司 | Compounding method and device of spartina alterniflora extract, chicory and gardenia jasminoides ellis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557352A (en) * | 2004-01-19 | 2004-12-29 | 北京中医药大学 | Novel usage of chicory aqueous extract |
-
2018
- 2018-04-27 CN CN201810392491.7A patent/CN108404019A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557352A (en) * | 2004-01-19 | 2004-12-29 | 北京中医药大学 | Novel usage of chicory aqueous extract |
Non-Patent Citations (6)
Title |
---|
朱继孝等: "栀子提取物降低小鼠急性高尿酸血症血尿酸水平及机理研究", 《安徽农业科学》 * |
朱继孝等: "栀子降尿酸有效部位研究", 《中国实验方剂学杂志》 * |
杨红莲等: "菊苣水提取物干预高嘌呤饮食诱导的鹌鹑尿酸及脂代谢紊乱的实验研究", 《中国中医药信息杂志》 * |
薛雪梅等: "高良姜不同提取物降尿酸及对黄嘌呤氧化酶抑制作用的实验研究", 《长江大学学报(自科版)》 * |
薛雪梅等: "高良姜总黄酮降尿酸作用研究", 《湖南中医杂志》 * |
黄胜男等: "菊苣干预高尿酸血症鹌鹑尿酸及相关代谢酶活性研究", 《中药新药与临床药理》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109511984A (en) * | 2019-01-09 | 2019-03-26 | 丁强 | A kind of special dietary seafood with the alleviation gout that celery seed, potassium citrate etc. are primary raw material preparation |
CN110051002A (en) * | 2019-04-28 | 2019-07-26 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine effect |
CN110393249A (en) * | 2019-09-08 | 2019-11-01 | 李丽 | A kind of witloof lily compound solid beverage product and preparation method thereof |
CN110859304A (en) * | 2019-11-26 | 2020-03-06 | 黑龙江惊哲森林食品集团有限公司 | Sunflower disc purine-reducing enzyme and preparation method thereof |
CN113425812A (en) * | 2021-08-06 | 2021-09-24 | 江苏菇神生物科技有限公司 | Compounding method and device of spartina alterniflora extract, chicory and gardenia jasminoides ellis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
AU2017101878A4 (en) | Gynostemma pentaphyllum containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia, and gout | |
CN109758571A (en) | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof | |
KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
CN106511641A (en) | Green plum and natto composition with gout treatment effect and preparation method thereof | |
CN107613998A (en) | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient | |
KR101371143B1 (en) | Composition comprising chlorella for improving liver function or relieving hangover | |
KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
CN107802770A (en) | Balance the Chinese medicine and health products of metabolic system radical cure early stage type II diabetes | |
JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
CN105176773A (en) | Pumpkin wine capable of adjusting blood glucose and making method thereof | |
KR101391647B1 (en) | Anti obesity composition | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
CN104286243A (en) | Selenium-enriched heart-nourishing tea and production method thereof | |
CN113662068A (en) | Formula and preparation method of osmanthus fragrans, medlar, ginger and sweet tea | |
KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
CN105105127A (en) | Multifunctional health food of haw heart easing powder | |
KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
CN108433051A (en) | A kind of digestant natural functional foods of tranquilization, stomach nourition | |
KR101391648B1 (en) | Anti obesity composition | |
JP5007995B2 (en) | Diabetes treatment using seaweed | |
CN106070794A (en) | One purifies the blood health protection tea and preparation method thereof | |
KR100478150B1 (en) | Health care food comprising an extract of the crude drug complex as an effective ingredient for preventing diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |
|
RJ01 | Rejection of invention patent application after publication |